Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBAL vs. Humira in healthy volunteers
NCT02206867Phase 1Completed
- Sponsor
- LG Chem
- Start
- Aug 2014
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA) and 6 more (2 arms), sponsored by LG Chem. Primary endpoints: Area under the concentration-time curve of the analyte in serum over the time interval from 0 extrapolated to infinity at 65 days and Maximum measured concentration of the analyte in serum at 65 days. Started Aug 2014; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)juvenile idiopathic arthritis (JIA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)Crohn's disease
Beyond the preview
Go deeper on NCT02206867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02206867.